WELL Health Technologies Corp.
TSX:WELL.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $947.00M
- Beta
- 1.33
- P/E (TTM)
- 41.6
- EPS (TTM)
- $0.11
Volume 2.80M
Average 1.62M
WELL.TO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
WELL Health Technologies Corp.TSX: WELL.TO
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of CA$10.22M (cash outflow) rose 87.7% year over year, ahead of the +62.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 20.5% from the prior quarter. Over 3 fiscal years it compounded at +63.3% a year.
Context
- Capital expenditures amounted to 2.0% of revenue in FY2025, up 0.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +87.7% holds above the trailing-twelve-month pace of +62.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CAD · from the cash flow
- Latest · FY2025
- (27.87M) CAD
- Year-over-year change
- -71.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.87M) | -71.8% |
| FY2024 | 2024-12-31 | (16.23M) | +36.1% |
| FY2023 | 2023-12-31 | (25.38M) | -296.4% |
| FY2022 | 2022-12-31 | (6.4M) | -138.8% |
| FY2021 | 2021-12-31 | (2.68M) | — |
Capital Expenditures vs competitors
How WELL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +62.7% is the 2nd highest of 5, against a peer median of -17.3%.
- Capital expenditures amounts to 2.2% of revenue for WELL.TO, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | CA$118.65M CAD | -28.6% | +35.2% | 10.7% | |
| LTM Jun 2026 | CA$90.4M CAD | +72.2% | +0.1% | 4.6% | |
| LTM Mar 2026 | CA$32.64M CAD | +62.7% | +63.3% | 2.2% | |
| LTM Mar 2026 | $12.43M USD | -53.1% | +73.2% | 7.8% | |
| LTM Mar 2026 | $5.72M USD | -6.0% | -9.6% | 1.9% | |
| Peer median (excluding WELL.TO) | — | -17.3% | +17.6% | 6.2% | |
Competitors are the stored peer set for WELL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.9M) | 18.68M | 82K | 29.1M | 4.46M |
| Depreciation & Amortization | 38.22M | 55.2M | 60.77M | 72.31M | 93.76M |
| Deferred Income Tax | 1.04M | (978K) | (10.42M) | (31.62M) | (16.38M) |
| Stock-Based Compensation | 21.01M | 24.48M | 26.16M | 15.27M | 22.69M |
| Change in Working Capital | (11.2M) | (6.06M) | (10.25M) | 6.67M | (36.7M) |
| Accounts Receivables | (13.27M) | (9.37M) | (2.49M) | (80.25M) | 47.3M |
| Inventory | 876K | (577K) | 190K | (1.51M) | 231K |
| Accounts Payables | 1.6M | 10.55M | (9.21M) | 36.42M | (20.12M) |
| Other Working Capital | (399K) | (6.67M) | 1.26M | 52.02M | (64.12M) |
| Other Non-Cash Items | 4.1M | (14.78M) | 95K | (82.21M) | 47.96M |
| Operating Cash Flow | 22.27M | 76.55M | 66.44M | 9.52M | 115.79M |
| Capital Expenditures | (2.68M) | (6.4M) | (25.38M) | (16.23M) | (27.87M) |
| Acquisitions (Net) | (421.76M) | (31.13M) | (72.78M) | (37.27M) | (80.51M) |
| Purchases of Investments | (3.12M) | (16.51M) | 0 | (73K) | 0 |
| Sales of Investments | 3.12M | 16.51M | 11.56M | 2.39M | 15.1M |
| Other Investing Activities | (75.33M) | (396K) | (19.82M) | (9.05M) | (18.47M) |
| Investing Cash Flow | (499.78M) | (37.93M) | (106.42M) | (60.23M) | (111.74M) |
| Debt Repayment | 171.07M | (58.75M) | 38.77M | (49.34M) | 157.6M |
| Common Stock Issued | 302.5M | 34.51M | 810K | 3.22M | 445K |
| Common Stock Repurchased | 0 | (243K) | 0 | (1.66M) | (1.83M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.04M) | 6.15M | (28.14M) | 136.85M | (155.28M) |
| Financing Cash Flow | 452.53M | (52.85M) | 10.63M | 133.5M | 941K |
| Effect of Forex Changes | 9K | 1.22M | (532K) | 4.75M | (2.91M) |
| Net Change in Cash | (24.97M) | (13.01M) | (5.49M) | 88.25M | 2.09M |
| Free Cash Flow | 19.59M | 70.14M | 37.2M | (6.7M) | 87.92M |
WELL Health Technologies Corp.
TSX:WELL.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.